Enterprise Value

141M

Cash

184.2M

Avg Qtr Burn

-27.75M

Short % of Float

21.07%

Insider Ownership

2.65%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Retifanlimab (anti-PD-1 mAb) Details
Solid tumor/s, Anal cancer, Non-small cell lung carcinoma, Lung cancer, Cancer

Phase 3

Data readout

Phase 2

Data readout

Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details
Castration-resistant prostate cancer, Cancer, Solid tumor/s

Phase 2

Data readout

Vobramitamab duocarmazine (vobra duo) (MGC018) Details
Castration-resistant prostate cancer, Solid tumor/s, Cancer

Phase 2

Data readout

Vobramitamab duocarmazine (vobra duo) w/lorigerlimab Details
Triple-negative breast cancer , Cancer, Melanoma, Castration-resistant prostate cancer, Solid tumor/s, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma

Phase 1/2

Data readout

MGD026 Details
Cancer, Solid tumor/s

Phase 1

Data readout

MGD024 Details
Acute myeloid leukemia, Myelodysplastic syndrome

Phase 1

Data readout

Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details
Cancer, Multiple myeloma, Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued

Enoblituzumab (anti-B7-H3) Details
Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued